Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins
Journal of Health, Wellness and Community Research · 15.01.2026 · e1375
DOI: 10.61919/bekv1p88 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health, Wellness and Community Research, online erschienen am 15.01.2026. Verfasst von Muhammad Salah Ud Din und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dyslipidaemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a leading modifiable risk factor for cardiovascular disease (CVD), which accounts for approximately 30–40% of adult mortality in Pakistan. Despite statin availability, LDL-C target attainment remains poor in high-risk Pakistani patients, necessitating evaluation of combination lipid-lowering strategies.
Objective
To compare the efficacy and safety of rosuvastatin monotherapy versus rosuvastatin-ezetimibe combination therapy in reducing LDL-C among high-risk cardiovascular patients at a tertiary care centre in Peshawar, Pakistan.
Methods
A retrospective cohort study was conducted between June 2022 and June 2023 (n = 150; 75 per arm). Adults aged 30–75 years with hypercholesterolaemia (LDL-C ≥100 mg/dL) and established CVD risk factors were included. Fasting lipid profiles were recorded at baseline and at 12 weeks. The primary outcome was absolute and proportional LDL-C reduction; secondary outcomes included changes in total cholesterol, triglycerides, HDL-C, and apolipoprotein B (ApoB). Between-group comparisons were performed using independent-samples t-tests, with Bonferroni correction applied for secondary outcomes.
Results
Baseline LDL-C was comparable between groups (144.12 ± 26.12 vs 142.46 ± 24.98 mg/dL; p = 0.681). At 12 weeks, LDL-C decreased to 91.60 ± 28.90 mg/dL in the rosuvastatin arm (36.5% reduction) and to 88.75 ± 29.73 mg/dL in the combination arm (37.7% reduction); the between-group difference was 2.85 mg/dL (95% CI: 0.39–5.31; p = 0.0234). Neither group achieved the guideline LDL-C target of
Zitieren
APA
Din, M. S. U., Adnan, M., Saeed, I., Abidullah, Ullah, N., & Faraz, N. (2026). Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins. Journal of Health, Wellness and Community Research, e1375. https://doi.org/10.61919/bekv1p88
Vancouver
Din MSU, Adnan M, Saeed I, Abidullah, Ullah N, Faraz N. Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins. Journal of Health, Wellness and Community Research. 2026:e1375. doi:10.61919/bekv1p88
BibTeX
@article{Din2026,
author = {Din, Muhammad Salah Ud and Adnan, Muhammad and Saeed, Ihtisham and Abidullah and Ullah, Nazeef and Faraz, Noor},
title = {Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins},
journal = {Journal of Health, Wellness and Community Research},
year = {2026},
pages = {e1375},
doi = {10.61919/bekv1p88}
}
EUVIMED